Publications by authors named "Andreas Machl"

Claim this Profile
E
Efficacy, safety, and biomarker analyses of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with advanced non-small cell lung cancer.
Arun Rajan, Houssein Abdul Sater, Osama Rahma, Richy Agajanian, Wiem Lassoued, Andreas Machl

J Immunother Cancer· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor growth inhibition modeling in patients with second line biliary tract cancer and first line non-small cell lung cancer based on bintrafusp alfa trials.
Ana-Marija Milenković-Grišić, Nadia Terranova, Diane R Mould, Yulia Vugmeyster, Thomas Mrowiec, Andreas Machl

CPT Pharmacometrics Syst Pharmacol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1-High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial.
Byoung Chul Cho, Jong Seok Lee, Yi-Long Wu, Irfan Cicin, Manuel Cobo Dols, Andreas Machl

J Thorac Oncol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 trial of bintrafusp alfa as second-line therapy for patients with locally advanced/metastatic biliary tract cancers.
Changhoon Yoo, Milind M Javle, Helena Verdaguer Mata, Filippo de Braud, Jörg Trojan, Andreas Machl

Hepatology· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bintrafusp Alfa: A Bifunctional Fusion Protein Targeting PD-L1 and TGF-β, in Patients with Pretreated Colorectal Cancer: Results from a Phase I Trial.
Alexander Spira, Michael S Wertheim, Edward J Kim, Benjamin Tan, Heinz-Josef Lenz, Andreas Machl

Oncologist· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to "Discovery of 4-aminopyrimidine analogs as highly potent dual P70S6K/Akt inhibitors" [Bioorgan. Med. Chem. Lett. 50 (2021) 128352].
Yufang Xiao, Bayard R Huck, Ruoxi Lan, Lizbeth DeSelm, Xiaoling Chen, Andreas Machl

Bioorg Med Chem Lett· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of 4-aminopyrimidine analogs as highly potent dual P70S6K/Akt inhibitors.
Yufang Xiao, Bayard R Huck, Ruoxi Lan, Lizbeth DeSelm, Xiaoling Chen, Andreas Machl

Bioorg Med Chem Lett· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of Clinical Candidate M2698, a Dual p70S6K and Akt Inhibitor, for Treatment of PAM Pathway-Altered Cancers.
Lizbeth DeSelm, Bayard Huck, Ruoxi Lan, Constantin Neagu, Justin Potnick, Andreas Machl

J Med Chem· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Small-Molecule Selective mTORC1 Inhibitors via Direct Inhibition of Glucose Transporters.
Seong A Kang, David J O'Neill, Andreas W Machl, Casey J Lumpkin, Stephanie N Galda

Cell Chem Biol· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
M2698 is a potent dual-inhibitor of p70S6K and Akt that affects tumor growth in mouse models of cancer and crosses the blood-brain barrier.
Andreas Machl, Erik W Wilker, Hui Tian, Xiaohong Liu, Patricia Schroeder

Am J Cancer Res· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improving DNA array data quality by minimising 'neighbourhood' effects.
Andreas W Machl, Christoph Schaab, Igor Ivanov

Nucleic Acids Res· November 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis